Skip to main content

Unable to load price data. Sorry.

¯\_(ツ)_/¯

Cambridge Heart, Inc. (NASDAQOTCBB:CAMH)

CAPS Rating: No stars

The Company is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease.

Unable to load market data for this Ticker. Sorry.

¯\_(ツ)_/¯

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

17 Outperform
13 Underperform
 

All-Star Players

3 Outperform
8 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQOTCBB:CAMH Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

paulmacdo (< 20)
Submitted April 28, 2007

This technology will become the standard for determining whether defibs are needed or not. Major clinical trials all support this. Another larege clinical trial is due in Nov, 2007. Insurance coverage already in place and more to come. Recent… More

SteadySaber (84.09)
Submitted January 01, 2007

I spoke with a few doctors and they pointed out that the ultimate users and buyers of this equipment have a disincentive to use it because they make more money installing the defibs and therefore don't want to find out what patients will not benefit… More

Recent Community Commentary

Read the most recent pitches from players about CAMH.

Recs

0
Member Avatar WindRules (< 20) Submitted: 6/15/2007 5:56:33 PM : Outperform Start Price: $4.43 NASDAQ OTC:CAMH Score: -315.51

Good product.
Numbers: -.16 this year, projected +.13 next year
PE from -28.26 to +33.69.
marketwatch
Their site: Increase in revenue from first quarter 2006 to first quarter 2007: 83%

Recs

1
Member Avatar paulmacdo (< 20) Submitted: 4/28/2007 11:58:18 AM : Outperform Start Price: $3.36 NASDAQ OTC:CAMH Score: -324.68

This technology will become the standard for determining whether defibs are needed or not. Major clinical trials all support this. Another larege clinical trial is due in Nov, 2007. Insurance coverage already in place and more to come. Recent marketing colaboration with STJ is going to propel sales and adoption. NASDAQ listing will also add to PPS appreciation. CAMH will explode over the 2 years.

Recs

0
Member Avatar aircarp (< 20) Submitted: 3/30/2007 10:26:31 PM : Outperform Start Price: $3.18 NASDAQ OTC:CAMH Score: -341.76

MTWA test now mandatory for Medicare and half of US insured prior to implant of an ICD.

New Sales and Marketing relationship with St. Jude (STJ). 2000 experienced and connected sales professionals will soon be selling the product.

FDA Approved. Patent Holder with mo Competition.

$120M+ Revenue target with 50-65% Margin = $25+ stock over next 2 years.

Leaderboard

Find the members with the highest scoring picks in CAMH.

Score Leader

donyao1

donyao1 (99.81) Score: +344.39

The Score Leader is the player with the highest score across all their picks in CAMH.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
donyao1 99.81 1/4/2007 Underperform 3Y $2.72 -99.45% +244.94% +344.39 0 Comment
SteadySaber 84.09 1/3/2007 Underperform 5Y $2.77 -99.46% +243.38% +342.85 10 Comments
smoaky 91.97 3/28/2007 Underperform 5Y $3.11 -99.52% +243.17% +342.69 0 Comment
cnwarner 21.26 1/31/2007 Underperform 5Y $2.65 -99.44% +242.23% +341.67 0 Comment
BigNORM9672 53.18 1/30/2007 Underperform 5Y $2.60 -99.43% +242.20% +341.63 0 Comment
gitau4ever 53.86 3/22/2007 Underperform NS $3.22 -99.54% +239.45% +338.99 1 Comment
plaidone 99.25 2/1/2007 Underperform 1Y $2.58 -99.42% +238.77% +338.19 1 Comment
in7rigue96 87.17 2/7/2007 Underperform 3M $2.31 -99.35% +236.68% +336.04 0 Comment
AlpacaInvestor 95.66 2/22/2007 Underperform 5Y $2.41 -99.38% +235.57% +334.96 0 Comment
jayahir < 20 11/6/2007 Underperform 3W $1.61 -99.07% +220.91% +319.99 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for CAMH.